Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen
Published in: Haematologica
Access to document
10.3324/haematol.2023.284672
document
Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise mechanisms of their involvement in control of the translocated oncogenes is limited. The goal of this project was to define the critical regions in the IGH regulatory elements and identify enhancer RNAs (eRNA). We...
Marta Elżbieta Kasprzyk, Weronika Sura, Marta Podralska, Marta Kazimierska, Annika Seitz, Wojciech Łosiewski, Tomasz Woźniak, Jeroen E J Guikema, Arjan Diepstra, Joost Kluiver, Anke Van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy
Published in: ESMO Open
Access to document
10.1016/j.esmoop.2024.103966
document
PURPOSE: Molecular tumor boards (MTBs) are considered beneficial for treatment decision making for patients with cancer with uncommon, rare, or complex mutational profiles. The lack of international MTB guidelines results in significant variation in practices and recommendations. Therefore, periodic follow-up is necessary to assess and govern MTB functioning. The objective of this study was to determine the effectiveness of MTB treatment recommendations for patients with rare and complex mutational profiles as implemented in the MTB of the University Medical Center Groningen (UMCG-MTB) in 2019-2020. PATIENTS AND METHODS: A...
V D de Jager, P Plomp, M S Paats, S van Helvert, A Ter Elst, A van den Berg, H J Dubbink, W H van Geffen, L Zhang, L E L Hendriks, T J N Hiltermann, B I Hiddinga, L B M Hijmering-Kappelle, M Jalving, J Kluiver, B Koopman, M van Kruchten, E M J van der Logt, B Piet, J van PuttenB H Reitsma, S R Rutgers, M de Vries, J A Stigt, M R Groves, W Timens, S M Willems, L C van Kempen, E Schuuring, A J van der Wekken
NEAT1 and CHROMR lncRNAs: a promising diagnostic tool for diffuse large B-cell lymphoma especially in elderly patients
Published in: Biomarkers in medicine
Access to document
10.1080/17520363.2024.2389036
Background: Long non-coding (lnc) RNAs have crucial regulatory roles in molecular pathways, and their dysregulation is associated with the pathogenesis of malignancies such as Diffuse large B-cell lymphoma (DLBCL). Therefore, we aimed to study the NEAT1 and CHROMR expression in DLBCL and explore their association with clinicopathological characteristics. Methods & materials: DLBCL and non-tumor lymph node specimens were obtained to assess the expression levels. Results: NEAT1 and CHROMR expressions were significantly increased in DLBCL, and were linked with the age of DLBCL patients (aged >60). NEAT1 and CHROMR...
Ali Rajabi, Ali Saber, Joost Kluiver, Anke van den Berg, Mohammad Ali Hosseinpourfeizi, Reza Safaralizadeh
Circular ZDHHC11 supports Burkitt lymphoma growth independent of its miR-150 binding capacity
Published in: Scientific Reports
Access to document
10.1038/s41598-024-59443-3
document
We previously showed that MYC promoted Burkitt lymphoma (BL) growth by inhibiting the tumor suppressor miR-150, resulting in release of miR-150 targets MYB and ZDHHC11. The ZDHHC11 gene encodes three different transcripts including a mRNA (pcZDHHC11), a linear long non-coding RNA (lncZDHHC11) and a circular RNA (circZDHHC11). All transcripts contain the same region with 18 miR-150 binding sites. Here we studied the relevance of circZDHHC11, including this miR-150 binding site region, for growth of BL cells. CircZDHHC11 was mainly present in the cytoplasmic fraction in BL cells and...
Yichen Liu, Xing Zhao, Annika Seitz, Annie A Hooijsma, Reyhaneh Ravanbakhsh, Sofia Sheveleva, Debora de Jong, Jasper Koerts, Agnieszka Dzikiewicz-Krawczyk, Anke van den Berg, Lotteke J Y M Ziel-Swier, Joost Kluiver
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Published in: BMC Cancer
Access to document
10.1186/s12885-024-12191-z
document
BACKGROUND: Primary central nervous system lymphoma (PCNSL) are rare mature B-cell lymphoproliferative diseases characterized by a high incidence of MYD88 L265P and CD79B Y196 hotspot mutations. Diagnosis of PCNSL can be challenging. The aim of the study was to analyze the detection rate of the MYD88 L265P and CD79B Y196 mutation in cell free DNA (cfDNA) in plasma of patients with PCNSL. METHODS: We analyzed by digital droplet PCR (ddPCR) to determine presence of the MYD88 L265P and CD79B Y196 hotspot mutations in cfDNA isolated from plasma of...